Accu-Break issues two new patents for their tablet-making technologies

PLANTATION, Fla. Accu-Break Pharmaceuticals announced the recent issuance of two patents for its Accu-Break technologies on Thursday. Accu-Break is widely known for its innovation in tablet formation that includes customized and individualized dosing, for patients that need specific amounts of a drug inserted for certain medications.

The first-patent involves a tablet designed for patients with combination doses that allows them to ingest only one tablet with two different medications. The new technology enables the medications to be separated by splitting the tablet through a drug free layer. This would also be helpful in combining two different medications that are not necessarily compatible with one another, without mixing them together.

The second patent, according to published reports, will include divisible tablets which would provide an accurate partial-dose of active ingredients within the tablet, which is useful for titration and doseage adjustment.

“The Company views the issuance of these patents as key to both our own product development and the worldwide licensing of our innovative tablet technologies,” said ABP’s chief executive officer, Allan Kaplan. “The granting of these patents should bode well for additional pending applications that cover, among other things, new and complimentary tablet technologies.”